Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
The Vietnamese pig farming industry is supported by a large, steady demand base, but it remains highly volatile due to price cycles and disease risks. As smallholder farming shrinks and large enterprises play a bigger role, companies with stronger control over the value chain are better positioned to manage costs…
Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for complex diseases, using genetic insights to guide its pipeline. The company’s focus includes renal and metabolic disorders, and it is advancing novel small molecule therapies through clinical development.
The complete disposition of all directly held Maze Therapeutics shares on April 1 by Chief Medical Officer Harold Bernstein is not necessarily a red flag. The sale was executed under a Rule 10b5-1 trading plan adopted in September 2025.
Rule 10b5-1 trading plans are commonly used by company insiders to help avoid allegations that trades were made based on material nonpublic information. In addition to the share sale, Bernstein retains more than 237,000 stock options.
Bernstein’s sale occurred during a period when Maze Therapeutics shares were declining. The stock reached a 52-week high of $53.65 in March following encouraging clinical trial data. After that run-up, investors began cashing in as the valuation rose, contributing to the subsequent decline in the share price.
Maze Therapeutics does not currently generate revenue. The company exited 2025 with a net loss of $131.1 million.
Despite the recent drop in the share price, investing in Maze Therapeutics carries high risk. Investors are expected to have confidence that the company’s lead kidney drug, MZE829, can ultimately obtain federal approval before buying shares.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
